PARPBP, a significant inhibitor of homologous recombination (HR), has been demonstrated to be related to increased AFP levels, proliferation, differentiation, and poor prognosis of lung and hepatocellular carcinoma patients (Yan et al., 2018; Su et al., 2020). Here, AFP is linked to hepatocellular carcinoma.